RUSH.A heads into its Q1 2026 earnings call with the print already on the table — and it's a split verdict.
Q1 EPS came in at $0.77, beating the $0.72 consensus by eight cents. Revenue of $1.68B, however, missed estimates by roughly $50M, landing below the analyst forecast of $1.72B. The stock closed the prior session at $75.31, down 1.2% on the day but up 14% over the past month — a run that had already priced in meaningful optimism heading into the announcement.
The most meaningful pre-print development was fresh analyst coverage. Wolfe Research initiated on April 27 with an Outperform rating and a $88 target — well above where the stock was trading and the clearest bullish signal from the Street in recent months. Stephens lifted its Overweight target to $80 back in February following the last print, while UBS maintained a Neutral stance with a $73 target. The Street's debate is clear: bulls point to strong per-unit revenue, robust vocational and public sector demand, and the expectation that Class 8 sales momentum carries into Q2. Bears flag the 4.6% year-over-year decline in parts and services revenue, a 70 basis point compression in gross margin, and the $50M revenue miss as evidence that volume softness is a real headwind.
Short positioning reflects no particular alarm. Short interest runs at 5.4% of the free float — a level that warrants attention but is far from a crowded short. It has been drifting higher over the past month, up roughly 10%, with most of the accumulation coming after April 9. Borrow remains cheap at 0.52% annualised, and availability is wide, suggesting shorts are not being squeezed and there is no meaningful pressure in the lending market. The ORTEX short score sits at 46.9, unremarkable and roughly in the middle of the range. Options are also calm — the put/call ratio is a very low 0.13, modestly above its 20-day average but near the bottom of its 52-week range, pointing to call-dominated positioning that aligns with the stock's recent upward move.
The insider picture is one-directional: every trade logged in the past 12 months has been a sale, with multiple executives — including the General Counsel and a Senior VP — booking gains in February after the last earnings pop. The CFO sold nearly $1M worth of shares in November 2024. None of these are distress signals, but the pattern of systematic selling into strength is worth noting as the stock trades near multi-year highs. FMR added nearly 1.8 million shares in Q1, the largest institutional move among top holders, providing a counterweight to insider outflows.
The print is now being digested: the question for the call is whether management's commentary on Q2 Class 8 delivery visibility and aftermarket revenue trends is enough to justify the premium that built up through April — or whether the revenue miss reopens the margin-pressure debate.
See the live data behind this article on ORTEX.
Open RUSH.A on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
